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Abstract: In our efforts to advance the profession and prac-
tice of clinical laboratory medicine, strong coordination 
and collaboration are needed more than ever before. At 
the dawn of the 21st century, medical laboratories are fac-
ing many unmet clinical needs, a technological revolution 
promising a plethora of better biomarkers, financial con-
straints, a growing scarcity of well-trained laboratory tech-
nicians and a sharply increasing number of International 
Organization for Standardization guidelines and new reg-
ulations to which medical laboratories should comply in 
order to guarantee safety and effectiveness of medical test 
results. Although this is a global trend, medical laborato-
ries across continents and countries are in distinct phases 
and experience various situations. A universal underlying 
requirement for safe and global use of medical test results 
is the standardization and harmonization of test results. 
Since two decades and after a number of endeavors on 
standardization/harmonization of medical tests, it is time 
to reflect on the effectiveness of the approaches used. To 
keep laboratory medicine sustainable, viable and afford-
able, clarification of the promises of metrological trace-
ability of test results for improving sick and health care, 
realization of formal commitment among all stakeholders 
of the metrological traceability chain and preparation of a 
joint and global plan for action are essential prerequisites. 
Policy makers and regulators should not only overwhelm 
the diagnostic sector with oversight and regulations but 
should also create the conditions by establishing a global 
professional forum for anchoring the metrological tracea-
bility concept in the medical test domain. Even so, profes-
sional societies should have a strong voice in their (inter-) 
national governments to negotiate long-lasting public 
policy commitment and funds for global standardization 
of medical tests.
Keywords: globalization; IVDR 2017/746; metrological 
traceability; test harmonization; test standardization.
Introduction
Medical laboratories in developed countries routinely 
produce millions of medical test results per year. Medical 
test results are highly relevant as the majority of down-
stream medical decisions are based on laboratory test 
results in pathology reports. Laboratory results are only 
meaningful if the results are interpreted through com-
parison to either population-specific reference intervals, 
clinical decision limits or previous results from the same 
patient (the so-called delta check) [1].
In making a comparison, it is vital that test results and 
reference intervals or decision limits are “comparable”. 
To that end, analytical bias, imprecision and selectivity 
of medical tests should be within predefined analytical 
performance specifications, in line with the EFLM Milan 
consensus hierarchy, which contributes to introduction of 
tests that are fit for clinical purpose [2]. If not, underdiagno-
sis and overdiagnosis occur in case of, e.g. disease-defin-
ing analytes such as Hb for anemia, glucose for gestational 
diabetes, HbA1c for diabetes mellitus and TSH/FT4 for sub-
clinical hypothyroidia. Comparable test results are essen-
tial in order to be able to apply Evidence-Based Laboratory 
Medicine principles, (inter)national clinical guidelines 
and common reference intervals or decision limits [3].
The process used to make different test results com-
parable is through implementation of the metrological 
traceability concept. According to its formal definition, 
metrological traceability is the property of a measure-
ment result whereby the result can be related to a reference 
through a documented unbroken chain of calibrations, each 
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contributing to the measurement uncertainty [4, 5]. Compa-
rable and traceable test results allow exchange of patient 
laboratory data on the local, national and global level. 
Non-comparable test results in Electronic Health Reports 
mislead doctors in their diagnosis and treatment in case 
that patients are, e.g. referred from primary to secondary or 
tertiary care settings, and bring along unacceptable man-
agement risk and additional costs in case of repeat testing.
Since 1947, attempts have been made to improve 
interlaboratory comparability of test results. History and 
updates have been described by renowned authors in 
recent editorials or other peer-reviewed literature [6–9]. 
Notwithstanding major scientific advances, appearance 
of international guidelines (global harmonization task 
force, ISO-guidelines, …) and landmark legislation (e.g. 
EU IVDD 98/79/EC and recently the EU IVDR 2017/746), 
the establishment of the Joint Committee on Traceability 
in Laboratory Medicine (JCTLM) in 2002, which publishes 
databases yielding approved Reference Materials, Refer-
ence Measurement Procedures and Reference Measure-
ment Systems, and the IVD manufacturer uptake of the 
metrological traceability concept, progress of medical 
test standardization/ harmonization in the past decen-
nia is experienced as too loose and too noncommit-
tal [8]. For too long, the pressing need for global test 
harmonization has been underrated and insufficiently 
integral addressed. The time is there that all stakehold-
ers involved with development, manufacture and use of 
in vitro diagnostic medical tests should join forces and 
take their responsibility, for the sake of sustainable and 
affordable laboratory medicine in the 21st century.
The role of regulators
Regulators aim to regulate the trade in active implant-
able Medical Devices, Medical Devices (MD) and In Vitro 
Diagnostic (IVD) Medical Devices on specific markets, and 
by doing so, to guarantee the safety, suitability and per-
formance as well as safeguard the health and ensure the 
necessary protection of patients, users and other persons 
(WHO-definition, 2001). This is a generic phenomenon 
worldwide, carried out by, e.g. the Therapeutic Goods 
Administration (TGA) Commonwealth Government agency 
in Australia, the US Food and Drug Administration (FDA) 
in the USA, the China Food and Drug Administration in 
China (CFDA) and the European Commission’s regulatory 
framework in the European Union (EU). International leg-
islation is periodically revised, and a global trend towards 
increased stringency is observed. As a representative 
example of stricter regulations, with impact on metrologi-
cal traceability of test results, the rationale and signifi-
cance of the latest EU legislation will be highlighted.
Due to a recent hip replacement scandal (2010) and 
a breast implant scandal (2012) causing harm to patients, 
regulators in the EU were forced to revise and strengthen 
the existing (active implantable) Medical Device Directives 
into formal Regulation (named EU MDR 2017/745). In par-
allel, the In Vitro Diagnostic (IVD) Medical Devices Direc-
tive 98/79/EC has concomitantly been transformed from 
a directive into an enforced regulation (named EU IVDR 
2017/746). Both regulations are officially published in the 
EU official journal and can be found at http://eur-lex.
europa.eu/legal-content/EN/TXT/?uri=OJ:L:2017:117:TOC. 
These regulations have entered into force on May 26, 2017, 
marking the start of a stormy transition period for compa-
nies bringing medical devices and IVDs on the European 
market. The product owners of IVDs are currently facing 
one of the greatest challenges ever, where all IVDs have 
to be categorized into respective risk classifications and 
where 80%–90% of the medical devices and IVDs have to 
undergo conformity assessment by notified bodies. This 
is a big contrast compared to the past situation under the 
EU Directives, where almost 80% of IVDs sold in Europe 
are controlled by the self-declaration mechanism. These 
regulations bring over legislation that is directly applica-
ble in EU-member states, not giving room for local inter-
pretation. Hence, medical laboratories face the shift and 
implementation from a “good will” approach into formal 
legal regulations, which have to be fully applied by May 
26, 2020 (MDR), and by May 20, 2022 (IVDR). The burden 
for IVD manufacturers is huge with this transition from a 
preapproval stage selection of medical devices and IVDs 
into a full life-cycle approach with regular updates either 
upon request (for class A and class B IVDs) or annually 
(for class C and class D IVDs).
The new EU regulations also impact medical labo-
ratories that perform in-house tests. Although health 
institutions running in-house tests are exempted from 
the regulations, several additional requirements have 
to be fulfilled. According to preamble 29 in the IVDR 
2017/746, health institutions should have the possibility 
of manufacturing, modifying and using in-house tests 
and thereby addressing, on a non-industrial scale, the 
specific needs of target patient groups, which cannot be 
met at the appropriate level of performance by an equiva-
lent device available on the market. In that context, it is 
foreseen that certain rules of the regulation, as regards 
in-house tests manufactured and used only within health 
institutions, including hospitals as well as institutions, 
such as laboratories and public health institutes that 
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support the health care system and/or address patient 
needs, but which do not treat or care for patients directly, 
do not apply, because the aims of this regulation would 
still be met in a proportionate manner. Additional require-
ments that EU health institutions running in-house tests 
should fulfill are as follows:
1. Manufacture and use within only one institution 
(“legal entity”);
2. Implementation of an appropriate quality manage-
ment system;
3. Compliance with EN ISO 15189 or further national 
requirements (e.g. accreditation);
4. Documentation that the health facility has given due 
consideration as to whether the target patient group’s 
specific needs cannot be met or cannot be met at the 
appropriate level of performance by an equivalent 
device available on the market;
5. Provide, upon request of the competent authority, 
information regarding the use of the in-house devices 
including a justification for manufacture, modifica-
tion, use;
6. Make publicly available a declaration of conformity 
with product details;
7. Present complete and detailed validation documen-
tation for IVDs of class D that enables the competent 
authority to assess whether the requirements are met;
8. Facilitate product monitoring during the entire life 
cycle of the device or IVD.
Metrological traceability in laboratory medicine – for both 
CE-IVDs and in-house tests – is internationally governed 
by ISO 17511:2003 and is a requirement of the original IVD 
Directive 98/79/EC in the EU. Both the ISO 17511:2003 guide-
line [In vitro diagnostic medical devices – Measurement of 
quantities in biological samples – Metrological traceability 
of values assigned to calibrators and control materials] and 
the EU Directive expect traceability of values assigned to 
calibrators and controls but do not literally prescribe the 
traceability of the end result for the patient. As the ISO 
17511:2003  has been in place for 15  years, it is currently 
under revision in ISO TC 212 WG 2. It can be anticipated 
that the new ISO 17511 version will solve this problem and 
will take into account metrological traceability of human 
samples, which is a big step forward to global harmoniza-
tion and standardization of test results. Disappointingly, 
the new IVDR 2017/746 in the EU does not prescribe that 
metrological traceability extends to the final patient’s 
result, which is a missed opportunity leading to a mis-
match with the new, upcoming ISO 17511. It remains to be 
seen how stakeholders will deal with this topic and what 
will be the consequences.
The role of professional and 
 scientific societies and academia
Principles on metrological traceability and measurement 
uncertainty are relatively new in laboratory medicine 
and gradually started gaining attention since the publi-
cation of the EU IVDD 98/79/EC Directive in 1998, which 
was fully applied in 2003. The metrological traceability 
concept diffused into the production processes of the IVD-
industry, with the help of JCTLM, ISO guidelines such as 
17511:2003 and the supportive activities of multiple refer-
ence laboratories.
Discussions with professional and scientific societies 
reveal that basic concepts in metrology and the science of 
measurement, including traceability and commutability, 
are generally not an integral part of academic or college 
curricula. It is obvious that professional societies of, e.g. 
laboratory medicine, should revise their curricula both in 
the non-academic and academic setting and add modules 
that guarantee basic knowledge and backgrounds on 
the relevance of metrological traceability, measurement 
uncertainty and commutability of secondary, matrix-
based reference materials [10–12] as essential prerequi-
sites for medical test equivalence in a global world.
Landmark textbooks for laboratorians such as the 
Tietz Textbook of Clinical Chemistry should also give suffi-
cient attention to the concepts of metrological traceability, 
measurement uncertainty and commutability. The Tietz 
Textbook of Clinical Chemistry describes these concepts 
in more detail since the 6th edition (2017), whereas the 
explanations were rather limited in the previous versions.
Since 2016, the JCTLM working group on Traceability, 
Education and Promotion (WG-TEP) produces and pro-
motes educational materials to demonstrate the value of 
traceability in laboratory medicine as a means to reduce 
between method variability in the interests of improved 
clinical outcomes and patient safety (https://www.jctlm.
org/about-us/).
The role of IFCC Executive Board 
and IFCC Scientific Division
Laboratory medicine has to operate in an ever chang-
ing context with an increasing number of stakeholders 
involved with either implementation (ISO 15189:2012) or 
oversight (new regulations such as the EU IVDR 2017/746) 
of the metrological traceability concept. In the test 
development phase, newly discovered biomarkers are 
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developed to medical tests in case they fulfill unmet clini-
cal needs and contribute to better patient outcome (i.e. the 
new test should have proven clinical effectiveness). Before 
medical tests can be put on the market, they should be 
CE-IVD marked and meet the stringent regulatory require-
ments of the IVDR. Manufacturing tests that give the right 
answers by means of traceable test results derived from 
useful medical tests and keeping pace with new regula-
tory demands is a challenging task.
The IFCC Scientific Division (SD) has a very important 
role in international test standardization c.q. harmoniza-
tion. Although the IFCC SD successfully manages stand-
ardization c.q. harmonization projects in six Committees 
and 17 Working Groups (http://www.ifcc.org/ifcc-scien-
tific-division/; accessed March 18, 2018) [13], the progress 
made with standardization/harmonization of tests by 
implementing the metrological traceability concept for 
single prioritized tests is slow and in volume not more than 
a drop in the ocean. That is only about 10%–15% of the 
routinely requested medical tests are well standardized.
The 21st century brings along population aging with 
increasing healthcare needs and struggles with finan-
cial constraints. Consequently, one can wonder whether 
the traditional approach of standardizing/harmonizing 
medical tests is sufficiently future proof and adequate. 
Also, the number of stakeholders involved in the oversight 
on the safety and effectiveness of medical tests further 
increases under the new MDR/IVDR as also designated 
notified bodies, competent authorities and expert labo-
ratories will have a role in the conformity assessment of 
medical devices and medical tests, before registration and 
market entry.
IFCC SD should likely reconsider its approach to 
advance the science of Clinical Chemistry and Laboratory 
Medicine and the application of the metrological traceabil-
ity concept to the practice of Clinical Laboratory Science, 
due to the new ISO 17511, the new MDR 2017/745 and IVDR 
2017/746, the generation Y with millennials who have 
huge expectations, the globalization of the MD and IVD 
markets and the urgent need for comparable test results in 
laboratory medicine because of globalization. Accelerated 
implementation of metrological traceability of test results 
and improved adoption and adherence of laboratory pro-
fessionals to metrology concepts likely demands adequate 
training and revised curricula, educational tools, innova-
tive approaches and collaborations with more clout, e.g. 
using flexible and e-proof network solutions and stand-
ardized approaches encompassing all relevant stake-
holders of the traceability chain. To make healthcare in 
general and laboratory medicine specifically more sus-
tainable, strong coalitions and overarching professional, 
non-voluntary structures have to be established between 
laboratory medicine, clinical and scientific societies, IVD 
manufacturers, reference material providers, metrology 
institutes and IFCC EB/SD.
The role of individual laboratory 
professionals
Laboratory professionals are expected to demonstrate 
clinical leadership by proactively taking their role in the 
adequate implementation of the metrological traceability 
concept. To that end, medical laboratory professionals 
should have deep awareness about the absolute neces-
sity of comparable test results and take coresponsibil-
ity for standardizing and harmonizing test results. They 
should have a clear ambition to contribute to equivalence 
of test results, according to the calibration hierarchies 
described in ISO 17511:2003 and its upcoming successor 
ISO 17511:20XX (under discussion in ISO TC 212 WG2). Lab-
oratory professionals should also take their responsibil-
ity as end users of CE-IVDs and in-house tests by selecting 
medical tests that have well-defined, clinically under-
stood measurands; adequate selectivity; correct units; and 
limited measurement uncertainty as deduced from their 
performance in EQA schemes. To that end, laboratory pro-
fessionals should principally select manufacturers who 
put into service CE-IVDs in line with the latest views on 
test standardization/harmonization and commutability, 
and who are transparent regarding their test traceability 
chains. Laboratory professionals should collectively have 
the ambition to add value by contributing to equivalent 
and traceable test results in a global world. Ambitions 
can only be realized if there are shared promises among 
all stakeholders of the traceability chain, and if there is 
constant commitment and proper action. That is all three 
components of the equation below should be in place.
Test Result Traceability and EquivalenceAmbition
Promises Commitment Action= ∗ ∗
Yet, lack of commitment towards the striving for 
traceability of patients’ test results in order to get the 
right answer for patient management can be deduced 
from typical decisions taken so far by medical laboratory 
directors. First, the fact that the majority of medical labo-
ratories still measure plasma creatinine (and pseudo-
chromogens) with non-selective Jaffé methods instead of 
more selective (enzymatic) methods, notwithstanding the 
consequences for chronic kidney disease classification, 
demonstrates the ignorance towards detrimental effects 
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of unselective tests on patient outcome. Second, notwith-
standing the fact that reference measurement systems are 
in place for, e.g. serum enzymes and/or plasma proteins 
since the nineties of the past century, there are still man-
ufacturers who bring CE-IVDs on the European market 
who are not standardized according to the latest insights. 
Third, laboratory professionals deny basic analytical 
chemistry principles due to an attitude of conservatism 
and/or pragmatism; i.e. so far, faulty mass units are used 
instead of mass-independent SI units for protein analytes 
that are genetically polymorph and/or very heterogene-
ous. Fourth, laboratory professionals select tests without 
knowing the measurands or the biologically active mole-
cular forms. Fifth, laboratory professionals agree with 
the coexistence of partly tuned reference measurement 
systems for the same analytes developed by different 
National Metrology Institutes and Reference Laboratories 
across the globe (e.g. for cholesterol, HbA1c,  C-peptide, 
etc.). Does our current uncritical behavior towards 
measurand definition, test selection and metrological 
traceability principles in contemporary medical labora-
tories mean that we are more bothered with budgetary 
constraints and providing efficient laboratory services 
rather than with getting the right answers by means of 
traceable test results derived from clinically effective tests 
that impact patient outcome with an acceptable benefit 
to harm ratio? Financial constraints are fact of life and 
should not take us away from the primary goal to improve 
patient outcome. In order to strengthen and not to further 
undermine the academic basis of laboratory medicine, 
the value of laboratory services for patient care, e.g. by 
standardizing or harmonizing medical tests, should come 
on the first place.
We conclude that standardization of medical tests in 
laboratory medicine is running behind as compared to 
standardization in other branches [8]. The lack of over-
arching professional structures that tightly engage all 
stakeholders responsible for implementing the traceabil-
ity concept and the voluntary participation of members 
hardly compare to the level of harmonization needs. To 
ultimately realize the ambition of comparable and trace-
able medical test results worldwide, shared promises, 
tight commitment and joint action by all stakeholders are 
essential. A quantum leap forward towards test standardi-
zation/harmonization requires a global approach with 
matching professional structures.
‘Knowing is not enough; we must apply.
Willing is not enough; we must do.’
Source: JW von Goethe
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